This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Rinvoq (upadacitinib)
General Description:
Rinvoq (upadacitinib) is a selective and reversible Janus kinase (JAK) inhibitor used to treat adults with active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.
By inhibiting the JAK pathway, Rinvoq helps reduce inflammation by blocking the signaling of specific cytokines involved in the immune response. This leads to relief from pain, stiffness, and swelling, while improving physical function and overall quality of life in patients with autoimmune and inflammatory diseases.
Disease Indications:
• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)
• Atopic Dermatitis (AD)
• Ulcerative Colitis (UC)
• Ankylosing Spondylitis (AS)
Manufacturer:
AbbVie Ltd
Usage:
Oral
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA)
Package:
• 30 extended-release tablets of 15 mg
• 30 extended-release tablets of 30 mg
• 28 extended-release tablets of 45 mg
Shipping:
Room Temperature Shipping
Rinvoq does not contain temperature-sensitive biological ingredients and therefore does not require cold chain delivery. Standard shipping conditions are maintained at a consistent room temperature of 15°C to 25°C during transit to ensure product stability and integrity.
This allows for easier handling and transportation while ensuring Rinvoq remains safe and effective for patient use.
How to Access Rinvoq (upadacitinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Rinvoq (upadacitinib) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in obtaining it legally through the Named Patient Program (NPP).
Here’s how the process works:
